Monoclonal antibodies to prevent severe COVID-19 aren't being used as widely as expected. Medical staff shortages and patient transportation problems are two of the reasons.
The experimental cocktail from the biotech company Regeneron is the same drug President Trump got when he was battling the coronavirus this year. It is designed for mild to moderate cases.
To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing.
